

Dietary determinants for Hb-acrylamide and Hb-glycidamide adducts in Danish non-smoking women

Malene Outzen^{1*}, Rikke Egeberg¹, Lars Dragsted², Jane Christensen¹, Pelle T. Olesen³, Henrik Frandsen³, Kim Overvad⁴, Anne Tjønneland¹ and Anja Olsen¹

¹Department of Diet, Cancer and Health, Institute of Cancer Epidemiology, Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen, Denmark

²Department of Human Nutrition, Faculty of Life Sciences, University of Copenhagen, Copenhagen, Denmark

³National Food Institute, Technical University of Denmark, Søborg, Denmark

⁴Department of Epidemiology, Institute of Public Health, Aarhus University, Aarhus, Denmark

(Received 11 May 2010 – Revised 13 October 2010 – Accepted 2 November 2010 – First published online 28 January 2011)

Abstract

Acrylamide (AA) is a probable human carcinogen that is formed in heat-treated carbohydrate-rich foods. The validity of FFQ to assess AA exposure has been questioned. The aim of the present cross-sectional study was to investigate dietary determinants of Hb-AA and Hb-glycidamide (GA) adducts. The study included 537 non-smoking women aged 50–65 years who participated in the Diet, Cancer and Health cohort (1993–97). At study baseline, blood samples and information on dietary and lifestyle variables obtained from self-administered questionnaires were collected. From blood samples, Hb-AA and Hb-GA in erythrocytes were analysed by liquid chromatography/MS/MS. Dietary determinants were evaluated by multiple linear regression analyses adjusted for age and smoking behaviour among ex-smokers. The median for Hb-AA was 35 pmol/g globin (5th percentile 17, 95th percentile 89) and for Hb-GA 21 pmol/g globin (5th percentile 8, 95th percentile 49). Of the dietary factors studied, intakes of coffee and chips were statistically significantly associated with a 4% per 200 g/d (95% CI 2, 7; $P < 0.0001$) and an 18% per 5 g/d (95% CI 6, 31; $P = 0.002$) higher Hb-AA, respectively. This model explained 17% of the variation in Hb-AA. Intakes of coffee and biscuits/crackers were statistically significantly associated with a 3% per 200 g/d (95% CI 1, 6; $P = 0.005$) and 12% per 10 g/d (95% CI 3, 23; $P = 0.01$) higher Hb-GA, respectively. This model explained 12% of the variation in Hb-GA. In conclusion, only a few dietary determinants of Hb-AA and Hb-GA were identified. Thus, the present study implies that dietary intake measured by an FFQ explains only to a limited extent the variation in Hb-AA and Hb-GA concentrations.

Key words: Acrylamide: Glycidamide: Hb-adducts: FFQ

Acrylamide (AA) is a human neurotoxin and is classified as a probable human carcinogen (class 2A) by the International Agency for Research on Cancer based on results from animal studies^(1–3). Earlier, AA exposure was thought to occur solely through tobacco smoke and occupational exposure^(4,5). In 2002, however, Swedish researchers detected AA in carbohydrate-rich foods (especially potato products) formed by Maillard reactions^(6–8), when these foods were prepared by frying, roasting or baking at temperatures above 120°C⁽⁹⁾. Since then, epidemiological studies have been conducted in the attempt to assess cancer risk according to dietary AA intake in human subjects^(10–16). The use of self-reported dietary intake from FFQ combined with databases including information regarding AA content measured in foods has

been the chosen method in these studies. Overall, most of the studies found no association between estimated dietary AA exposure and cancer risk for different sites^(10–16).

Recently, attempts to clarify whether the apparent null associations between dietary AA intake and cancer risk reported in most studies are evident, or whether they merely are the consequences of inappropriate measurements of dietary AA exposure by FFQ, have been made. A way to overcome the problem of inappropriate measurement of dietary AA exposure by FFQ could be the use of an objective biomarker of AA exposure. Hb-AA adducts and the epoxy metabolite of AA, Hb-glycidamide (GA) adducts, have been used. These have been shown to reliably reflect the internal dose of the adducts during 120 d before blood sampling in

Abbreviations: AA, acrylamide; GA, glycidamide; LOQ, limit of quantification.

* **Corresponding author:** M. Outzen, fax +45 35257731, email outzen@cancer.dk

accordance with the lifetime of erythrocytes⁽¹⁷⁾. Hb-AA has been found to reflect the general exposure to AA⁽⁴⁾, whereas Hb-GA is a biomarker of the internal dose of GA⁽¹⁸⁾. These metabolites have been used for the validation of FFQ-estimated dietary AA intake, but published studies have shown varying results^(19–24).

So far, only two studies have related AA exposure to cancer risk by the use of biomarkers reflecting AA exposure^(23,25), of which one found a significant positive association between Hb-AA and the risk for oestrogen receptor-positive breast cancer⁽²⁵⁾.

As AA is a probable carcinogen to human subjects, it is important to identify the food sources that predict Hb-adduct levels. The direct relationship of diet measured by FFQ and Hb-adduct concentrations has only been reported in two previous studies, both limited by few participants^(19,21). The aim of the present study was to investigate to what extent dietary variables estimated from an FFQ were able to predict the Hb-AA and Hb-GA adduct concentrations in a large population of non-smoking women attending the Danish Diet, Cancer and Health cohort.

Materials and methods

Study population

A population of 868 postmenopausal women from a nested case–control study in the prospective Diet, Cancer and Health cohort were selected for the present study⁽²⁵⁾. The Diet, Cancer and Health cohort was established with the primary aim of investigating the aetiological role of diet on cancer previously described in detail⁽²⁶⁾. Briefly, between December 1993 and May 1997, a total of 79 729 Danish women living in the greater Copenhagen and Aarhus areas were invited to participate in the cohort. The criteria for invitation were age between 50 and 64 years, born in Denmark and no previous diagnosis of cancer registered in the Danish Cancer Registry. The invited women were identified by the unique ten-digit identification number that is allocated to every Danish citizen by the Central Population Registry. Among the invited women, a total of 29 875 agreed to participate, corresponding to a participation of 37%⁽²⁶⁾. The Diet, Cancer and Health study and the present study were conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures involving human subjects were approved by the Regional Ethical Committees on human studies in Copenhagen and Aarhus, and by the Danish Data Protection Agency. Written informed consent was obtained from all subjects.

Of the 868 women included in the present study, nineteen women were excluded due to a lack of blood sample or sample loss during the Hb-adduct analyses, eight were excluded due to missing information on selected variables (smoking or diet) and four were excluded due to outlying values for the selected variables. Finally, 300 women were excluded due to being a current smoker at baseline, leaving a total of 537 non-smoking women for the analyses.

Data collection

All participants attended one of two established study centres in Copenhagen or Aarhus. The responders received by mail a 192-item semi-quantitative FFQ and completed this before attending the study centres. Development and validation of the FFQ have been described previously^(27–30). Women were asked to report their average intake of foods and beverages during the last 12 months within twelve possible categories ranging from never to ≥ 8 times/d. The calculations of the daily intake of specific foods and nutrients for each participant were conducted using the software program FoodCalc⁽³¹⁾, using specifically developed standardised recipes and portion sizes.

Dietary variables selected for the statistical analyses in the present study were only food items that were known to contain an appreciable amount of AA, and were available from the FFQ. The following dietary variables were chosen and quantified into the following quantities: 200 g/d for coffee; 20 g/d for cereals (oatmeal, rye bread, refined bread, whole-grain bread and crispbread); 5 g/d for potatoes (baked, fried and chips); 10 g/d for cakes and chocolate (pound (sand) cake, Danish pastry, biscuits/crackers and chocolate); 5 g/d for snacks (peanuts, crisps and cracklings). The quantities reflected the observed variation in intake in this population (considered from the interquartile range). The population had a quite low intake of the included food items (Table 1), and therefore, these increments in daily intake were chosen.

Table 1. Baseline characteristics of the 537 non-smoking women (Number of subjects, medians and percentiles)

Variable	n*	Median	Percentile	
			5th	95th
Age (years)		57	51	64
Hb-AA (pmol/g globin)		35	17	89
Hb-GA (pmol/g globin)		21	8	49
Coffee (g/d)	507	500	29	1300
Cereals (g/d)	537	121	42	229
Oatmeal	310	21	1	50
Rye bread	534	63	11	113
Refined bread	419	13	0.5†	75
Whole-grain bread	510	40	3	100
Crispbread	442	2	0.2†	30
Potatoes (g/d)	527	14	4	65
Baked potatoes	499	3	2	14
Fried potatoes	496	5	2	21
Chips	359	1	1	7
Cakes and chocolate (g/d)	537	15	3	65
Sand cake	468	2	1	26
Danish pastry	496	3	1	32
Biscuits/crackers	524	1	0.1†	15
Chocolate	525	4	1	21
Snacks (g/d)	468	3	1	21
Peanuts	395	1	1	7
Crisps	422	1	1	7
Cracklings	180	1	1	4

AA, acrylamide, GA, glycidamide.

* n indicates the number of the non-smoking women having an intake of the given variable.

† The value is zero when rounded off to the nearest whole number.

At the study centres, each woman had a non-fasting blood sample taken and were asked to fill in a questionnaire dealing with questions about lifestyle habits, including alcohol and smoking behaviours, reproductive factors, health status and social factors. Anthropometrical measurements such as weight and height were carried out by professional staff members for every cohort participant; BMI was calculated as weight (kg) divided by height squared (m^2).

Analytical method

The blood samples were analysed for Hb-adducts at the National Food Institute, Denmark, in accordance with the method previously described by detail by Bjellaas *et al.*⁽¹⁹⁾. Briefly, from the thawed erythrocyte fractions, globin was purified and stored at -20°C until further analysis. Globin was subjected to a modified Edman reaction, where phenyl isothiocyanate reacts with N-terminal amino acid (valine) in Hb, undergoes cyclisation and decouples from the Hb molecule releasing a phenylthiohydantoin derivative of N-alkylated valine adducts. The released phenylthiohydantoin derivatives were purified by solid-phase extraction and analysed in triplicate on a liquid chromatography ion-trap MS using multiple reaction monitoring. In total, forty-two batches were run.

The limit of quantification (LOQ) was 2.4 pmol/g for Hb-AA and 7.3 pmol/g for Hb-GA.

Statistical methods

The study population in the present study included women from a nested case-control study, and therefore, a test for heterogeneity between cases and controls was performed using a linear regression. No statistically significant differences between case and control status for Hb-AA ($P_{\text{heterogeneity}} = 0.30$) or for Hb-GA ($P_{\text{heterogeneity}} = 0.73$) were found.

Women who smoked at blood sampling were excluded, as smoking is a major source of AA exposure⁽⁴⁾, and we were concerned about not being able to completely adjust for this potentially strong confounder. Smoking exposure, however, is expected to be of short term^(32,33), and it was therefore considered to retain ex-smokers in the present study. The combined group of never- and ex-smokers did not differ from either never- or ex-smokers in Hb-adduct concentrations. Furthermore, when excluding ex-smokers, who discontinued smoking within the year before blood sampling, no appreciable difference between recent ex-smokers and never-smokers was observed. Therefore, ex-smokers and never-smokers were included in the analyses.

Multiple linear regression analysis was applied to model the associations between the intake of AA-rich foods and Hb-adduct concentrations. The Hb-adduct concentrations were log-transformed to improve normality of the distributions. Linearity was tested for all continuous variables by linear splines with three or nine boundaries placed at the quartiles and by an F test⁽³⁴⁾. The smoking variables (time since cessation and duration) were log-transformed in order to be linear. For all other variables, we found no departure from linearity.

The association between dietary sources of AA and Hb-adduct concentrations was analysed using a one-way ANOVA and was adjusted for age as well as time since smoking cessation (among ex-smokers) and duration of smoking (among ex-smokers) to correct for a potential small residual effect of previous smoking. The estimates were back-transformed to describe the percentage difference in Hb-adduct concentrations for a defined difference in the intake of a given food item. The estimates were presented as the percentage change in Hb-adduct concentrations and the related 95% CI and P values. Furthermore, the explained variation in the Hb-adduct concentrations from the mutually adjusted model was assessed by R^2 values.

All Hb-AA concentrations were above the LOQ, and linear regression procedures (general linear model; GLM) were used. For Hb-GA, nineteen samples were below the LOQ value, and therefore, a parametric model with left censoring was used (LIFEREG). Levels of Hb-GA below the LOQ were afterwards handled as left-censored. The model is also known as the Tobit model⁽³⁵⁾.

The R^2 value could not be calculated for the mutually adjusted model for Hb-GA since the LIFEREG procedures were used. To calculate an R^2 value, all values below the LOQ were allocated one value representing all of the values below the LOQ. To evaluate the impact of choosing one representing value, different values were allocated (LOQ = 4, LOQ = 5, LOQ = 6 and LOQ = 7) and analysed in different models using the general linear model procedure. The estimates were visually considered in each model and compared with the estimates from LIFEREG. No marked difference was observed, and the R^2 value from the model with LOQ = 5 was chosen.

The procedures general linear model (GLM) and LIFEREG in the Statistical Analysis Systems statistical software package release 9.1 (SAS Institute, Cary, NC, USA) were used for the analyses on a TextPad platform.

Results

Baseline characteristics of the 537 non-smoking women included in the study are shown in Table 1. The median age at entrance to the study was 57 years (5th percentile 51, 95th percentile 64). The median Hb-AA concentration was 35 pmol/g globin (5th percentile 17, 95th percentile 89), and the median Hb-GA concentration was 21 pmol/g globin (5th percentile 8, 95th percentile 49).

Table 2 shows the estimates for the association between dietary variables and the Hb-adduct concentrations and the corresponding 95% CI and P values in a minimally and a mutually adjusted model. In the minimally adjusted model, a higher intake of coffee was statistically significantly associated with a 5% per 200 g/d (95% CI 3, 7; $P < 0.0001$) higher Hb-AA concentration, whereas a higher intake of chips was statistically significantly associated with a 20% per 5 g/d (95% CI 9, 33; $P = 0.0004$) higher Hb-AA concentration. When mutual adjustments were performed, these associations persisted, as higher intakes of both coffee and chips were statistically significantly associated with a 4% per 200 g/d (95% CI 2, 7;

Table 2. Estimates indicating the associations between dietary variables and the Hb-adduct concentrations among the 537 non-smoking women in the Diet, Cancer and Health Cohort

(Δ Estimates and 95 % confidence intervals)

	Hb-AA						Hb-GA					
	Minimally adjusted*†			Mutually adjusted†‡			Minimally adjusted*†			Mutually adjusted†‡		
	Δ	95 % CI§	P	Δ	95 % CI§	P	Δ	95 % CI§	P	Δ	95 % CI§	P
Coffee per 200 g/d	5	3, 7	<0.0001	4	2, 7	<0.0001	4	2, 6	0.0006	3	1, 6	0.005
Cereals per 20 g/d												
Oatmeal	-1	-6, 4	0.57	0	-5, 5	0.94	-3	-8, 3	0.38	-1	-7, 4	0.60
Rye bread	-1	-3, 2	0.61	-1	-3, 1	0.34	-1	-3, 1	0.41	-2	-4, 1	0.21
Refined bread	-1	-5, 3	0.55	0	-4, 3	0.80	2	-2, 6	0.35	2	-2, 6	0.46
Whole-grain bread	0	-2, 2	0.96	0	-2, 3	0.68	-1	-3, 1	0.27	-1	-3, 2	0.65
Crispbread	5	-5, 16	0.33	9	-1, 20	0.10	7	-4, 20	0.23	11	-1, 24	0.07
Potatoes per 5 g/d												
Baked potatoes	1	0, 3	0.07	1	0, 3	0.17	1	-1, 2	0.56	0	-1, 2	0.59
Fried potatoes	1	-1, 2	0.36	-1	-2, 1	0.31	2	0, 4	0.04	1	-1, 2	0.49
Chips	20	9, 33	0.0004	18	6, 31	0.002	15	3, 29	0.02	10	-2, 23	0.10
Cakes and chocolate per 10 g/d												
Pound cake	0	-4, 4	0.99	-1	-5, 4	0.72	3	-2, 8	0.22	1	-3, 6	0.59
Danish pastry	2	-1, 5	0.28	1	-2, 5	0.43	4	0, 8	0.03	3	-1, 7	0.11
Biscuits/crackers	7	-1, 16	0.10	8	-1, 17	0.07	13	3, 23	0.009	12	3, 23	0.01
Chocolate	2	-2, 6	0.42	2	-1, 6	0.22	2	-3, 6	0.46	2	-2, 6	0.41
Snacks per 5 g/d												
Peanuts	-2	-6, 3	0.43	-2	-7, 2	0.31	-2	-6, 4	0.55	-3	-7, 2	0.27
Crisps	6	-1, 13	0.10	4	-3, 11	0.28	3	-4, 11	0.42	1	-6, 9	0.71
Cracklings	6	-12, 28	0.51	9	-10, 32	0.38	13	-8, 39	0.25	17	-5, 45	0.13
R^2		-	-	0.17		-		-	-	0.12		-

AA, acrylamide; GA, glycidamide; LOQ, limit of quantification; GLM, general linear model.

* Univariate models.

† Adjusted for smoking variables (duration (years, continuous), time since cessation (years, continuous) and smoking status (never/ex) and age (years, continuous).

‡ Each food item mutually adjusted.

§ Δ Estimates reported as the percentage difference in Hb-adduct concentration per defined unit of difference in dietary variables.

|| The R^2 value could not be calculated for the mutually adjusted model for Hb-GA since the LIFEREG procedures were used. To calculate an R^2 value, all values below the LOQ were allocated one value representing all of the values below the LOQ. To evaluate the impact of choosing one representing value, different values were allocated (LOQ = 4, LOQ = 5, LOQ = 6 and LOQ = 7) and analysed in different models using the GLM procedure. The estimates were visually considered in each model and compared with the estimates from LIFEREG. No marked difference was observed. The presented R^2 value is from the model with LOQ = 5.

$P < 0.0001$) and an 18 % per 5 g/d (95 % CI 6, 31; $P = 0.002$) higher Hb-AA concentration in the mutually adjusted model (Table 2). This model explained 17% of the variation in Hb-AA concentration.

In the minimally adjusted analyses for Hb-GA, intakes of the following dietary variables were statistically significantly associated with a higher Hb-GA concentration: coffee (percentage difference 4 % per 200 g/d; 95 % CI 2, 6; $P = 0.0006$), fried potatoes (percentage difference 2 % per 5 g/d; 95 % CI 0, 4; $P = 0.04$), chips (percentage difference 15 % per 5 g/d; 95 % CI 3, 29; $P = 0.02$), Danish pastry (percentage difference 4 % per 10 g/d; 95 % CI 0, 8; $P = 0.03$) and biscuits/crackers (percentage difference 13 % per 10 g/d; 95 % CI 3, 23; $P = 0.009$). When mutual adjustments were performed, only higher intakes of coffee and biscuits/crackers were statistically significantly associated with a 3 % per 200 g/d (95 % CI 1, 6; $P = 0.005$) and a 12 % per 10 g/d (95 % CI 3, 23; $P = 0.01$) higher concentration, respectively. This model explained 12 % of the variation in Hb-GA concentration.

Discussion

In a sample of 537 non-smoking Danish postmenopausal women, only a few dietary determinants of Hb-adduct concentrations in the blood were identified. The most important

determinants of the Hb-AA concentration were coffee and chips. The most important determinants of the Hb-GA concentration were coffee and biscuits/crackers. Overall, the FFQ only explained 17% of the variation in the Hb-AA concentration and 12% of the variation in the Hb-GA concentration. The strengths of the present study are the use of both Hb-AA and Hb-GA as objective biomarkers of AA exposure, and a considerably higher statistical power compared with previous studies. Further strengths include the use of a validated FFQ to obtain information on dietary intake and the availability of detailed information on several lifestyle factors including our ability to exclude smokers. The most important limitations concern the FFQ used, which was not specifically designed to obtain information on AA-containing food items. The AA content of food items has been shown to vary considerably⁽³⁶⁾, and the standard foods in the FFQ used might therefore be a problem. The use of a standard FFQ probably limits the chance of identifying associations between the dietary determinants and the Hb-adduct concentrations. For example, in other studies, crisps have been shown to contain a high amount of AA^(9,37), but in the present study, crisps were not found to be a strong determinant of the Hb-adduct concentrations.

Two previous studies have examined dietary determinants in relation to Hb-adduct concentrations among non-smokers^(19,21).

A Norwegian study (n 44) found, unlike the present study, that intake of coffee was not a statistically significant determinant of Hb-AA⁽¹⁹⁾. Additionally, the Norwegian study found that intakes of potato products and crisp bread were positive, statistically significant determinants of Hb-AA⁽¹⁹⁾. An American study (n 296) also showed processed potato products as a positive, statistically significant determinant of Hb-AA⁽²¹⁾. The American study also evaluated dietary determinants of Hb-GA; particularly, intakes of coffee and potato products were positive, statistically significant determinants of Hb-GA⁽²¹⁾.

In the present study, only 17% of the Hb-AA concentration and 12% of the Hb-GA concentration were explained by the dietary factors studied. In one of the previous studies, potential AA-rich foods were found to explain 48% of the Hb-AA variation⁽¹⁹⁾. The FFQ in the previous Norwegian study was composed after the findings of AA in foods, and detection of AA-rich foods may therefore have been considered in the design of this FFQ. The American study did not present the percentage of explained variation. Several factors may be related to the observed poor ability of FFQ to explain the Hb-adduct variation, but the most important is probably the pronounced variation of AA in foods; food properties (e.g. concentration of reducing sugars)⁽³⁸⁾, processes during the production (e.g. process temperature)⁽³⁹⁾ and the presence of specific dietary components (e.g. rosemary)^(40,41) are all strongly related to AA content or formation, and are impossible to assess by FFQ.

In addition to problems related to FFQ, other factors possibly affecting the results exist. Large inter-individual variations in the Hb-adduct concentrations have been observed between populations⁽⁴²⁾, which might be due to variations in genes important in AA metabolism^(43–45). This possible genetic variation and gene–environment interactions may have affected AA metabolism in the present study population, which might result in inter-individual variations in Hb-adduct levels. Such variation will increase the random error, and the ability of the dietary factors to explain the variation in Hb-adduct levels might be masked.

In human subjects, a high reproducibility of Hb-adduct concentrations over time based on two blood samples has been shown⁽²¹⁾, indicating that one blood sample as collected in the present study is sufficient, when using Hb-adducts as a marker for AA exposure. However, more blood samples drawn during the year could correct for potential seasonal variation in Hb-adduct concentrations.

In the present study, three dietary factors were found to be statistically significantly associated with a higher Hb-adduct concentration, namely coffee (Hb-AA and Hb-GA), chips (Hb-AA) and biscuits/crackers (Hb-GA). The intake of these food items in the studied population varied considerably; the population had high intakes of coffee but rather low intakes of chips and biscuits/crackers (Table 1). It may seem surprising that chips and biscuits/crackers despite the lower amounts eaten still were found to be significantly related to Hb-adduct levels. They are, however, very well-known AA sources and were apparently able to distinguish AA intake even in this low intake population.

In previous studies, the sum of Hb-AA and Hb-GA has been included^(19,21), as the sum has been assumed to reflect the overall measure of AA exposure. Hb-AA levels have, however, been shown to be strongly correlated with the total exposure of AA^(4,46–48), and may therefore be considered as a good marker of AA exposure. In the present study, it was therefore considered reasonable to include the Hb-adducts separately.

In the present study, negative associations between several dietary factors and Hb-adduct levels were shown. No factors were found to be statistically significantly associated with a lower Hb-adduct level. But several tendencies were found (for Hb-AA: rye bread, fried potatoes, pound cake and peanuts; for Hb-GA: oatmeal, rye bread, whole-grain bread and peanuts), though all associations were of a very limited magnitude. Also, the study by Bjellaas *et al.*⁽¹⁹⁾ discovered a negative association, though for jam/preservatives. It seems biologically unlikely that any of the studied food items should be negatively associated with Hb-adduct concentrations, as the dietary factors studied are known to have considerable AA contents. An explanation for the negative associations observed could be unknown confounding factors.

In conclusion, dietary factors measured by an FFQ could only to a limited extent predict Hb-adduct levels. Our finding supports the assumption that FFQ are inadequate measuring instruments for dietary AA exposure, especially when the FFQ is not specifically designed to measure AA intake. The null findings obtained between estimated dietary AA intakes in relation to cancer risk in most of the previous studies may therefore be caused by misclassification of dietary AA exposure as a consequence of an inaccuracy of FFQ in the estimation of dietary AA exposure. To investigate AA exposure in relation to cancer risk in future studies, the use of biomarkers reflecting the AA exposure is possibly a better measure for AA exposure.

Acknowledgements

We acknowledge Katja Boll (data manager) and Jytte Fogh Larsen (project coordinator) for their assistance with the collection and handling of data. We also acknowledge Joan E. Frandsen and Helle E. Gluver (laboratory technicians, National Food Institute, Technical University of Denmark) for their technical assistance with the determination of Hb-AA and Hb-GA. The present study was supported by funds from Nord-Forsk (the Nordic Center of Excellence HELGA). The funding agency had no influence on the design and conduct of the study; collection, management, analysis and interpretation of the data; or preparation, review or approval of the manuscript. A. T. and K. O. contributed to the original design and data collection for the Diet, Cancer and Health project. A. O. contributed to the development of the hypothesis and study design. P. T. O. and H. F. performed the Hb-AA and Hb-GA analyses. M. O. performed the statistical analysis under the supervision of J. C. and wrote the manuscript. R. E., L. D. and A. O. contributed to the interpretation of results and made critical comments during the preparation of the manuscript. All authors contributed to the writing of the manuscript and approved the final version. There are no conflicts of interest to report.

References

- Hagmar L, Tornqvist M, Nordander C, *et al.* (2001) Health effects of occupational exposure to acrylamide using hemoglobin adducts as biomarkers of internal dose. *Scand J Work Environ Health* **27**, 219–226.
- Calleman CJ, Wu Y, He F, *et al.* (1994) Relationships between biomarkers of exposure and neurological effects in a group of workers exposed to acrylamide. *Toxicol Appl Pharmacol* **126**, 361–371.
- International Agency for Research on Cancer (1994) *Acrylamide: Monographs on the Evaluation of Carcinogenic Risks to Humans: Some Industrial Chemicals*, vol. 60, pp. 389–433. Lyon: IARC.
- Bergmark E (1997) Hemoglobin adducts of acrylamide and acrylonitrile in laboratory workers, smokers and nonsmokers. *Chem Res Toxicol* **10**, 78–84.
- European Commission, European Chemicals Bureau & Institute for Health and Consumer Protection (2002) *European Union Risk Assessment Report, Acrylamide*. Luxembourg: Office for Official Publications of the European Communities. http://ecb.jrc.ec.europa.eu/documents/Existing-Chemicals/RISK_ASSESSMENT/REPORT/acrylamidereport011.pdf (accessed 25th March 2010).
- Mottram DS, Wedzicha BL & Dodson AT (2002) Acrylamide is formed in the Maillard reaction. *Nature* **419**, 448–449.
- Stadler RH, Blank I, Varga N, *et al.* (2002) Acrylamide from Maillard reaction products. *Nature* **419**, 449–450.
- Zyzak DV, Sanders RA, Stojanovic M, *et al.* (2003) Acrylamide formation mechanism in heated foods. *J Agric Food Chem* **51**, 4782–4787.
- Tareke E, Rydberg P, Karlsson P, *et al.* (2002) Analysis of acrylamide, a carcinogen formed in heated foodstuffs. *J Agric Food Chem* **50**, 4998–5006.
- Larsson SC, Hakansson N, Akesson A, *et al.* (2009) Long-term dietary acrylamide intake and risk of endometrial cancer in a prospective cohort of Swedish women. *Int J Cancer* **124**, 1196–1199.
- Larsson SC, Akesson A & Wolk A (2009) Dietary acrylamide intake and prostate cancer risk in a prospective cohort of Swedish men. *Cancer Epidemiol Biomarkers Prev* **18**, 1939–1941.
- Mucci LA & Adami HO (2009) The plight of the potato: is dietary acrylamide a risk factor for human cancer? *J Natl Cancer Inst* **101**, 618–621.
- Pedersen GS, Hogervorst JG, Schouten LJ, *et al.* (2010) Dietary acrylamide intake and estrogen and progesterone receptor-defined postmenopausal breast cancer risk. *Breast Cancer Res Treat* **122**, 199–210.
- Hogervorst JG, Schouten LJ, Konings EJ, *et al.* (2009) Lung cancer risk in relation to dietary acrylamide intake. *J Natl Cancer Inst* **101**, 651–662.
- Hogervorst JG, Schouten LJ, Konings EJ, *et al.* (2009) Dietary acrylamide intake and brain cancer risk. *Cancer Epidemiol Biomarkers Prev* **18**, 1663–1666.
- Schouten LJ, Hogervorst JG, Konings EJ, *et al.* (2009) Dietary acrylamide intake and the risk of head–neck and thyroid cancers: results from The Netherlands cohort study. *Am J Epidemiol* **170**, 873–884.
- Tornqvist M, Fred C, Haglund J, *et al.* (2002) Protein adducts: quantitative and qualitative aspects of their formation, analysis and applications. *J Chromatogr B Analyt Technol Biomed Life Sci* **778**, 279–308.
- Paulsson B, Athanassiadis I, Rydberg P, *et al.* (2003) Hemoglobin adducts from glycidamide: acetonization of hydrophilic groups for reproducible gas chromatography/tandem mass spectrometric analysis. *Rapid Commun Mass Spectrom* **17**, 1859–1865.
- Bjellaas T, Olesen PT, Frandsen H, *et al.* (2007) Comparison of estimated dietary intake of acrylamide with hemoglobin adducts of acrylamide and glycidamide. *Toxicol Sci* **98**, 110–117.
- Kutting B, Uter W & Drexler H (2008) The association between self-reported acrylamide intake and hemoglobin adducts as biomarkers of exposure. *Cancer Causes Control* **19**, 273–281.
- Wilson KM, Vesper HW, Tocco P, *et al.* (2008) Validation of a food frequency questionnaire measurement of dietary acrylamide intake using hemoglobin adducts of acrylamide and glycidamide. *Cancer Causes Control* **20**, 269–278.
- Wirfalt E, Paulsson B, Tornqvist M, *et al.* (2008) Associations between estimated acrylamide intakes, and hemoglobin AA adducts in a sample from the Malmo Diet and Cancer cohort. *Eur J Clin Nutr* **62**, 314–323.
- Wilson KM, Balter K, Adami HO, *et al.* (2009) Acrylamide exposure measured by food frequency questionnaire and hemoglobin adduct levels and prostate cancer risk in the Cancer of the Prostate in Sweden Study. *Int J Cancer* **124**, 2384–2390.
- Hagmar L, Wirfalt E, Paulsson B, *et al.* (2005) Differences in hemoglobin adduct levels of acrylamide in the general population with respect to dietary intake, smoking habits and gender. *Mutat Res* **580**, 157–165.
- Olesen PT, Olsen A, Frandsen H, *et al.* (2008) Acrylamide exposure and incidence of breast cancer among postmenopausal women in the Danish Diet, Cancer and Health Study. *Int J Cancer* **122**, 2094–2100.
- Tjonneland A, Olsen A, Boll K, *et al.* (2007) Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: a population-based prospective cohort study of 57,053 men and women in Denmark. *Scand J Public Health* **35**, 432–441.
- Haraldsdottir J, Tjonneland A & Overvad K (1994) Validity of individual portion size estimates in a food frequency questionnaire. *Int J Epidemiol* **23**, 786–796.
- Overvad K, Tjonneland A, Haraldsdottir J, *et al.* (1991) Development of a semiquantitative food frequency questionnaire to assess food, energy and nutrient intake in Denmark. *Int J Epidemiol* **20**, 900–905.
- Tjonneland A, Overvad K, Haraldsdottir J, *et al.* (1991) Validation of a semiquantitative food frequency questionnaire developed in Denmark. *Int J Epidemiol* **20**, 906–912.
- Tjonneland A, Haraldsdottir J, Overvad K, *et al.* (1992) Influence of individually estimated portion size data on the validity of a semiquantitative food frequency questionnaire. *Int J Epidemiol* **21**, 770–777.
- Lauritsen J (1998) Foodcalc 1.3. [computer program]. <http://www.foodcalc.dk> (accessed 25th March 2010).
- Schettgen T, Rossbach B, Kutting B, *et al.* (2004) Determination of haemoglobin adducts of acrylamide and glycidamide in smoking and non-smoking persons of the general population. *Int J Hyg Environ Health* **207**, 531–539.
- Smith CJ, Perfetti TA, Rumble MA, *et al.* (2000) “IARC group 2A Carcinogens” reported in cigarette mainstream smoke. *Food Chem Toxicol* **38**, 371–383.
- Greenland S (1995) Dose–response and trend analysis in epidemiology: alternatives to categorical analysis. *Epidemiology* **6**, 356–365.
- Greenland S (1995) Avoiding power loss associated with categorization and ordinal scores in dose–response and trend analysis. *Epidemiology* **6**, 450–454.

36. FAO/WHO (2006) Joint FAO/WHO Food Standards Programme, Codex Committee on Food Additives and Contaminants, Discussion Paper on Acrylamide: Thirty-eight Session, The Hague, The Netherlands, 24–28 April 2006. ftp://ftp.fao.org/codex/ccfac38/fa38_35e.pdf>ftp://ftp.fao.org/codex/ccfac38/fa38_35e.pdf (accessed 25th March 2010).
37. Svensson K, Abramsson L, Becker W, *et al.* (2003) Dietary intake of acrylamide in Sweden. *Food Chem Toxicol* **41**, 1581–1586.
38. Seal CJ, de Mul A, Eisenbrand G, *et al.* (2008) Risk–benefit considerations of mitigation measures on acrylamide content of foods – a case study on potatoes, cereals and coffee. *Br J Nutr* **99**, Suppl. 2, S1–S46.
39. Amrein TM, Andres L, Escher F, *et al.* (2007) Occurrence of acrylamide in selected foods and mitigation options. *Food Addit Contam* **24**, Suppl. 1, 13–25.
40. Becalski A, Lau BP, Lewis D, *et al.* (2003) Acrylamide in foods: occurrence, sources, and modeling. *J Agric Food Chem* **51**, 802–808.
41. Hedegaard RV, Granby K, Frandsen H, *et al.* (2008) Acrylamide in bread. Effect of prooxidants and antioxidants. *Eur Food Res Technol* **227**, 519–525.
42. Vesper HW, Slimani N, Hallmans G, *et al.* (2008) Cross-sectional study on acrylamide hemoglobin adducts in subpopulations from the European Prospective Investigation into Cancer and Nutrition (EPIC) Study. *J Agric Food Chem* **56**, 6046–6053.
43. Doroshenko O, Fuhr U, Kunz D, *et al.* (2009) *In vivo* role of cytochrome P450 2E1 and glutathione-S-transferase activity for acrylamide toxicokinetics in humans. *Cancer Epidemiol Biomarkers Prev* **18**, 433–443.
44. Duale N, Bjellaas T, Alexander J, *et al.* (2009) Biomarkers of human exposure to acrylamide and relation to polymorphisms in metabolizing genes. *Toxicol Sci* **108**, 90–99.
45. Paulsson B, Rannug A, Henderson AP, *et al.* (2005) *In vitro* studies of the influence of glutathione transferases and epoxide hydrolase on the detoxification of acrylamide and glycidamide in blood. *Mutat Res* **580**, 53–59.
46. Fennell TR, Sumner SC, Snyder RW, *et al.* (2005) Metabolism and hemoglobin adduct formation of acrylamide in humans. *Toxicol Sci* **85**, 447–459.
47. Tareke E, Twaddle NC, McDaniel LP, *et al.* (2006) Relationships between biomarkers of exposure and toxicokinetics in Fischer 344 rats and B6C3F1 mice administered single doses of acrylamide and glycidamide and multiple doses of acrylamide. *Toxicol Appl Pharmacol* **217**, 63–75.
48. Urban M, Kavvadias D, Riedel K, *et al.* (2006) Urinary mercapturic acids and a hemoglobin adduct for the dosimetry of acrylamide exposure in smokers and nonsmokers. *Inhal Toxicol* **18**, 831–839.